The WHO Global Technical Strategy for Malaria 2016–2030 provides a framework and key targets for all malaria-endemic countries working towards control and elimination. Reaching these targets will contribute to achieving Sustainable Development Goal 3 ‘Ensure healthy lives and promote well-being for all at all ages’. In 2020, MMV and key partners made important strides towards meeting these targets by:

**Accelerating efforts towards elimination and attainment of malaria-free status**

- Marketing authorization application of tafenoquine paediatric submitted to Australian Therapeutic Goods Administration
- Ganaplcide–lumefantrine (frontunner new combination therapy) progressed to Part B of the Phase Iib trial, with an additional paediatric study (KALUMI) starting in 2021
- Cipargamin new formulation for intravenous administration completed Phase I with Phase II expected to start in 2021
- To date, 6,500 new data points have been generated from transmission-blocking assays performed in collaboration with Imperial College London

**Ensuring universal access to malaria prevention and treatment**

- 2.7 million lives estimated to have been saved to date through MMV-supported medicines
- 536 million courses of SPAQ delivered since its launch in 2014 for seasonal malaria, protecting over 30 million children in 2020. Six new combinations of licensed molecules have been evaluated and ranked as alternatives to SPAQ for SMC.
- 430 million paediatric treatment courses of Coartem® Dispersible (artemether–lumefantrine) distributed to over 50 countries since 2009, saving an estimated 926,000 lives
- 1.73 million patients treated with Pyramax® (pyronaridine–artesunate); tablets approved in 29 countries and granules in 19 countries
- 209 million vials of injectable artesunate delivered since launch, estimated to have saved 1.36 million additional lives compared to treatment with injectable quinine
- 7.9 million Eurartesim® (dihydroartemisinin–piperaquine) treatments distributed since approval with registration in 24 countries
- Three new regulatory approvals for Kringle/Kozanis (tafenoquine), including in Thailand, the first South East Asian country to grant marketing authorization approval
- 3.8 million doses of artesunate rectal capsules delivered to date with registration in 17 countries, saving an estimated 443,000 lives
- Over 100 Pandemic Response Boxes shipped in 2019–2020 to facilitate drug discovery in other disease areas
- Two compounds active against Plasmodium cynomolgi liver stages identified through screening
- Over 50 COVID Boxes shipped to enable standardization of testing results across various laboratories

**Harnessing innovation and expanding research**

- Four new late leads approved in 2020
- New candidate selected for development: ELQ331
- 11 compounds in preclinical and clinical development including 10 with novel biological pathways compared with existing ACTs
- Over 50 COVID Boxes shipped to enable standardization of testing results across various laboratories

**Strengthening the enabling environment**

- European and Developing Countries Clinical Trials Partnership (EDCTP)-funded PAMAfrica training to strengthen research capacity at trial sites and research capability of next-generation African scientists
- Implemented measures to support supply chains for chloroquine to treat malaria in P. vivax-endemic countries and mitigate stockouts
- Promoted healthcare awareness in rural communities adapting existing malaria educational initiatives, e.g. training community health volunteers on danger signs and protocols around COVID-19

**Safeguarded continued SMC campaigns, protecting 30 million children in 2020**

- A new pregnancy registry has been established to monitor the impact of different antimalarials on mother and child, inform policymakers and strengthen healthcare systems

**Working beyond our scope: Response to the COVID-19 pandemic**

- Over 100 Pandemic Response Boxes shipped in 2019–2020 to facilitate drug discovery in other disease areas
- Two compounds active against Plasmodium cynomolgi liver stages identified through screening
- Three new regulatory approvals for Kringle/Kozanis (tafenoquine), including in Thailand, the first South East Asian country to grant marketing authorization approval
- 3.8 million doses of artesunate rectal capsules delivered to date with registration in 17 countries, saving an estimated 443,000 lives
- Over 100 Pandemic Response Boxes shipped in 2019–2020 to facilitate drug discovery in other disease areas
- Two compounds active against Plasmodium cynomolgi liver stages identified through screening
- Four new late leads approved in 2020
- New candidate selected for development: ELQ331
- 11 compounds in preclinical and clinical development including 10 with novel biological pathways compared with existing ACTs
- Over 50 COVID Boxes shipped to enable standardization of testing results across various laboratories
- Promoted healthcare awareness in rural communities adapting existing malaria educational initiatives, e.g. training community health volunteers on danger signs and protocols around COVID-19

**Promoted healthcare awareness in rural communities adapting existing malaria educational initiatives, e.g. training community health volunteers on danger signs and protocols around COVID-19**

| Milestones 2020 | Staying true to our malaria mission in a time of global uncertainty |

---

1. MMV Global Technical Strategy for Malaria 2016–2030
2. UN Sustainable Development Goals (SDGs) (https://www.who.int/sustainable-development-goals#tab=) for malaria 2016–2030. (https://www.who.int/docs/pdf?sfvrsn=c82afcc_0)
3. Tafenoquine is marketed by or licensed to the GSK group of companies. Trademarks are owned by or licensed to the GSK group of companies.
4. Assuming that patients would have received injectable quinine in the absence of injectable artesunate.